FUM Stock Overview
Research, develops, and sells pharmaceutical and healthcare products for sexual health.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.36 |
| 52 Week High | UK£0.53 |
| 52 Week Low | UK£0.23 |
| Beta | 1.25 |
| 11 Month Change | 6.34% |
| 3 Month Change | 4.73% |
| 1 Year Change | -29.81% |
| 33 Year Change | -14.12% |
| 5 Year Change | 14.06% |
| Change since IPO | -48.95% |
Recent News & Updates
Recent updates
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)
Sep 13
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Shareholder Returns
| FUM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.7% | -2.9% | -0.1% |
| 1Y | -29.8% | 10.6% | 5.7% |
Return vs Industry: FUM underperformed the UK Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: FUM underperformed the UK Market which returned 7.1% over the past year.
Price Volatility
| FUM volatility | |
|---|---|
| FUM Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: FUM has not had significant price volatility in the past 3 months.
Volatility Over Time: FUM's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 12 | James Barder | www.futuramedical.com |
Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Futura Medical plc Fundamentals Summary
| FUM fundamental statistics | |
|---|---|
| Market cap | UK£110.18m |
| Earnings (TTM) | -UK£3.75m |
| Revenue (TTM) | UK£8.40m |
13.1x
P/S Ratio-29.4x
P/E RatioIs FUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUM income statement (TTM) | |
|---|---|
| Revenue | UK£8.40m |
| Cost of Revenue | UK£2.71m |
| Gross Profit | UK£5.69m |
| Other Expenses | UK£9.44m |
| Earnings | -UK£3.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 67.70% |
| Net Profit Margin | -44.68% |
| Debt/Equity Ratio | 0% |
How did FUM perform over the long term?
See historical performance and comparison